HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of ...
On October 28, 2022, ESSA Pharma Inc (NASDAQ:EPIX) announced multiple poster presentations at the 29th Annual Prostate Cancer Foundation Scientific Retreat, including an update on the Phase 1/2 Study ...
On February 13, 2020, ESSA Pharma Inc. (NASDAQ:EPIX) announced additional preclinical data was presented at the 2020 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (the ...
VANCOUVER and HOUSTON, April 30, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the ...
On January 19, 2022, ESSA Pharma, Inc. EPIX announced that the first patient has been dosed in the Phase 1/2 clinical trial of EPI-7386 and enzalutamide in patients with metastatic ...
First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: ...
Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC). This is an ASCO Meeting Abstract from the 2023 ASCO ...
HOUSTON and VANCOUVER, BC, Jan. 13, 2021 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...
“Why you can trust Digital Trends – We have a 20-year history of testing, reviewing, and rating products, services and apps to help you make a sound buying decision. Find out more about how we test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results